You can rely on $NOVO B (-0,7%) can be relied on. What do you think, should we take the opportunity and buy more? Then hope, believe, etc

Hello everyone,

First of all, let me introduce myself: I'm Robin, 20 years old and I'm just about to finish my apprenticeship. I have already been involved in crypto and share trading for about 1-2 years on and off and have also made small investments, which I would now like to expand and deepen after completing my education.

As I am still pretty much at the beginning, I would like to ask you for tips and advice.

In order to learn more in general, I would also like to buy a book or two on the subject of investing. This brings me to my first question:

• Can you guys recommend any books or other resources? Of course you can find a lot on the internet, but unfortunately there is also a lot of misleading information or products that are supposed to make money but ultimately don't help. I'm also simply missing some technical terms and certainly some basic knowledge that I would like to learn and understand before I get fully involved with investing.

I also have other questions that some of you with more experience may be able to answer better and more easily:

• Why can it be advantageous to buy shares/stocks of a company (e.g. $NOVO B (-0,7%) ) despite a constantly falling share price?

I have already read individual posts on this subject and have noticed that opinions on the company are sometimes very divided. However, I am increasingly seeing that many investors are using it to expand or further increase their portfolio.

• How do you analyze shares comprehensively before deciding to invest?

This is a very general question, so the answer here is probably too broad. I would therefore like to refer back to my first question about books. Surely there are books, platforms, social media channels, etc. that go into this in depth and can explain it in the best possible way. I would be very grateful for any suggestions or experiences.

• Why are some shares (e.g. $VOW (+0,86%) ) are not always in such high demand despite their high dividend yield?

I follow news and I am aware that VW is not the best choice at the moment (e-car demand, profit slump, ...). In my opinion, it is a stable company with a high dividend yield and yet is not as sought after as expected. Are there specific reasons for this or is it just due to the current situation?

• Conversely, there are shares (e.g. $BLK , $GOOGL (-1,98%) ) that are in greater demand despite a comparatively low dividend yield. Are we simply expecting an increase in the share price or why are such shares also in high demand when you can simply buy shares with a high dividend yield?

• Finally, I have a question about the share portfolio. It is of course advantageous to diversify your investments (ETFs, shares, crypto). There are a lot of large companies in various sectors in which you can buy shares. Do you have any recommendations for a good allocation so that it is not too one-sided in one area?

Of course, I could find all this out myself through my own research & and I would like to do that - but a little help with tips & advice would help me a lot to get started.

I look forward to hearing from you and thank you for your answers :)

$NOVO B (-0,7%) Simply add an additional €50 savings plan per month 👍🏻

Good morning to all "loss-realizers" and "paperhands" - Yes, I can see you tearing your hair out over the current Novo Nordisk share price ($NOVO B (-0,7%) ) is making you tear your hair out. But let's be honest: What has changed? Nothing! Except maybe your nerves, which are now thinner than a post-Christmas diet plan.

Novo Nordisk remains the same brutal companythat has been pleasing - or torturing, depending on how you look at it - the diabetics and slimmers of this world for years. Wegovy and Ozempic are running like hotcakes, and the pipeline is as full as a wallet after the next paycheck.

But of course, because the share price stutters a little, it's time to say: "Sell everything!" - as if we were at a flea market. The same people who, at €130 "To the moon!" are now shouting "Crash!" - Typical stock market psychology, isn't it?

My tip: If you get weak now, don't complain later if the rocket takes off without you. At €45 there will be the next tranche - and who knows, maybe we really will see ourselves at the top again. Or we could simply wait until the next "all-time high party" is due - it's sure to come.

#NovoNordisk
#Wegovy
#Paperhands
#LangfristigOderGarNicht
#AufLock

(P.S.: Anyone who sells now has also bought Bitcoin at 30k and sold at 18k. Just saying. 😏)

Hello dear GetQuin Community.

I would be interested in your thoughts on the following positions, I have been thinking about investing in them for a while.

What do you think?

$IEEM (+0,02%)

$AI (+0,08%)

$CVE (-0,19%)

$NOVO B (-0,7%)

$TSM (+0,97%)

Press the cost price a little :D

Now only -21% at x91

$NOVO B (-0,7%)

The latest announcements by the US government to impose import duties on pharmaceutical products are casting a shadow over European pharmaceutical companies. Novo Nordisk, the Danish market leader in diabetes and obesity therapy, is particularly in the spotlight.

🔍 Background

Novo Nordisk generates over 60% of its sales in North America, while only around a fifth of its production takes place there. This discrepancy makes the company vulnerable to trade barriers. Analysts estimate that a hypothetical 20% US tariff on Novo Nordisk's products could reduce the company's EBITA by up to 10% in 2025.

Chart 1:

📉 Potential negative impact

- Margin pressureIf tariffs of e.g. 20% are imposed on pharmaceutical products, Novo Nordisk would either have to increase prices in the US (which is politically and regulatory difficult) or reduce margins - which has a direct impact on EBIT.

- Supply chain complexityThe introduction of tariffs could force Novo Nordisk to relocate parts of its production to the US to avoid additional costs. However, such restructuring requires significant investment and time. They could also disrupt the company's global supply chain and affect the availability of medicines.

- Regulatory challengesDuties could result in additional regulatory requirements that make market access more difficult and increase administrative costs.

Figure 2:

📈 Potential opportunities

- Reshoring as an advantageNovo Nordisk is already expanding new production capacities in the USA. If the supply chain becomes more local, tariffs could even become less important in the medium term.

- Political tailwindAs a provider of medicines for widespread diseases (e.g. diabetes, obesity), Novo Nordisk generally enjoys a high political standing - which is in contrast to more tariff-critical industries such as automotive or technology.

- DiversificationThe company has a broad global base, which somewhat cushions the risks of individual markets.

Chart 3:

📊 Infographic: Potential impact on EBIT (estimate)

The following chart shows the estimated impact of a hypothetical 20% tariff on Novo Nordisk's EBIT:

⚠️ Note:

This article does not constitute investment advice. All content is for information purposes only and does not replace individual advice. Please inform yourself independently before making any investment decisions.

🔖 Hashtags for reach & context:

#NovoNordisk
#Zölle
#USHandelspolitik
#Anlagestrategie
#Makroökonomie
#Pharma
#Fed
#Inflation
#Aktienanalyse
#GetQuin
#Investieren
#Wirtschaftspolitik
#EBIT
#TradeWar

Sources:

Graphic 1:

https://goldesel.de/artikel/die-zukuenftig-wertvollsten-unternehmen-der-welt

Graph 3:

https://finanzmarktwelt.de/usa-zoelle-wie-zu-zeiten-der-weltwirtschaftskrise-die-gefahren-338163/

$NOVO B (-0,7%) The chart shows the period from the strong price performance in March/April 2021. From this point onwards, the price was supported by strong momentum and closely followed the red line, which represents the second standard deviation of the VWAP (Volume Weighted Average Price). This second standard deviation ran quite parallel above the SMA50 until the trend reversed in July 2024.

The significant volume peaks were in the price ranges around € 51, € 70 and € 83. Numerous positions were built up between April and November 2022, particularly in the €51 range. The price is currently at the lower edge of the first standard deviation of the VWAPwhich lies exactly on one of these volume peaks. From a technical perspective, this could represent a strong support zone. The next few weeks, up to the earnings on 7 May, will show whether institutional investors defend their trades from this area.

A positive scenario would be a bounce up to the next volume peak around € 70 or even beyond to above the VWAP (blue line). A negative scenario on the other hand, could mean a fall in the share price to around € 40.

After the share price reached the lower edge of the first standard deviation of the VWAP yesterday, I increased my Novo position by a further 10%. Despite the current price losses, which are likely to affect many investors, the fundamental figures make me optimistic about the future.

• Estimates for sales and EPS for the next few years are still rising
• P/E ratio, KUV and KBV are at the same levels as in 2018
• Gross margin is >80%, EBITDA margin >50%,
• Cash flow from operating activities continues to rise.

Some have already pulled the ripcord and exited $NOVO B (-0,7%) exited. My position is already quite large for my individual share positions with a total of 220 shares, so I may well adjust the position size again slightly in the event of a bounce. Let's see what happens after the earnings on May 7?

How do you see Novo? Have you already pulled the ripcord, or do you have strong nerves and are taking advantage of the current price weakness to expand a market leader in the diabetes sector?

@Sebi I would also like to see a picture including RSI and MACD - thanks for pointing this out - I'm sure many people will find it interesting!